AlphaRX Inc. Enters into National Sales and Marketing Agreement with Acosta Canada for Line of OTC Drugs and Nutraceuticals

AlphaRX Inc. Enters into National Sales and Marketing Agreement with Acosta Canada for Line of OTC Drugs and Nutraceuticals

AlphaRX Inc. Enters into National Sales and Marketing Agreement with Acosta Canada for Line of OTC Drugs and Nutraceuticals

RICHMOND HILL, Ontario, Sep 19, 2002 (BUSINESS WIRE) -- AlphaRx Inc.
(OTCBB: ALRX) is pleased to announce it has entered into a sales and marketing
agreement with Acosta Canada Corporation for its current product line of
over-the-counter drugs and nutritional supplements. Acosta is a national sales
and marketing company offering sales and support services in numerous different
channels, including grocery, drug, specialty, convenience and mass merchandisers
such as Wal-Mart, Kmart and Target. Acosta has international divisions, making
it one of the leading consumer product distributors in the world.

AlphaRx's current product line consists of proprietary topical analgesics,
(Flexogan(TM) Arthritis Pain, Flexogan(TM) Muscle Pain, Flexogan(TM) Sport and
Flexogan(TM) Sport Ultra), oral care and health products and a full line of
nutraceuticals including LipoBloc(TM) and LipoLette(TM), proprietary dietary
formulations addressing the multi-billion dollar markets for the management of
high blood cholesterol levels and the promotion of sustainable long-term bodily
weight-control.

AlphaRx's C.E.O., Michael Lee stated "This is a significant corporate milestone
for us. We are excited about the revenue growth and brand recognition that will
result from this relationship. Our national sales campaign will be followed by
an international sales and marketing strategy to be executed in 2003."

    About Acosta

    http://www.acosta.com

Acosta Corporation is an international leader in sales and marketing solutions,
providing services to worldwide manufacturers of consumer products with more
than 1100 associates in over 75 locations. Services include retail selling
execution, creative trade and consumer marketing programs, customer service and
order processing. Outlets include grocery stores, mass merchandisers/club
stores, convenience stores, drug stores and other specialty stores.

    About AlphaRx

AlphaRx is engaged in the development of novel formulations of drugs that are
insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists
of carefully selected, currently marketed drugs, which, through the application
of its proprietary drug delivery technology, offer improved medical benefits
over existing products with a strong commercial potential.

    FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant
to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995
and involve risks and uncertainties that may individually or mutually impact the
matters herein described, including but not limited to product development and
acceptance, manufacturing, competition, regulatory and/or other factors, which
are outside the control of the Company.

Note: The FDA has not evaluated these statements. This statement is not intended
to diagnose, treat, cure of prevent disease.

CONTACT:         AlphaRx

                 Brad Caister, 905/762-0745 Ext. 238            

                 http://www.alpharx.com                    ;

                 or                                        

                 Econ Investor Relations

                 Dawn Van Zant, 888/368-8705    

                 dvanzant@investorideas.com